HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM





Influenza Prevention and Outbreak Management in SNF 2021-22

10.27.2021

Healthcare-Associated Infections Program Center for Health Care Quality California Department of Public Health



Objectives

- Describe the epidemiology of influenza, SARS-CoV-2, and other respiratory viruses in California
- Describe background and key messages about prevention of influenza during the COVID-19 pandemic
- Describe guidance for planning and managing influenza and SARS-CoV-2 co-circulation in SNF
- Describe the role of the local health department (LHD) in influenza prevention and outbreak management





What will be different this flu season?



- Influenza seasons vary in severity from year to year, based on the characteristics of the circulating influenza virus strains and how well the vaccine matches the circulating strains
- Co-circulation of influenza and SARS-CoV-2 viruses has been documented
- Frequency, severity, risk factors, interactions unpredictable
 - Concern about predominance of A(H3N2) influenza A strain in the southern hemisphere 2021



HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM

Influenza Activity Up To 10/10/2021 – WHO



Globally: Flu activity lower than expected for time of year < 1% flu tests 9/27-10/10/21 pos. Flu B 66% (Victoria) Flu A 34%, 66% A(H3N2) RSV increased in many areas

https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/ influenza-updates/current-influenza-update



SARS-CoV-2 in California SNF as of 10/25/2021





HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM



https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/ Week2021-2241 FINALReport.pdf



HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM Percentage of Influenza Detections at Clinical Sentinel Labs 2017-2022



Season to date: pos. 0.4%, sporadic, 3 cases Flu B in 3 different LTCF



HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM Percentage of Respiratory Pathogen Detection at Clinical Sentinel Labs, California 2020-2021



As of 10/16/21: 8.2% RSV pos. (decreasing; usual peak Dec-March pre-COVID Parainfluenza, non SARS-CoV-2 coronaviruses, rhino/entero increased

Reasons for Low Influenza Activity During 2020-21 Season

- COVID-19 mitigation measures
 - Wearing face masks
 - Staying home
 - Hand hygiene
 - School closures
 - Reduced travel
 - Increased ventilation of indoor spaces
 - Physical distancing
 - ? Viral interference

 How will COVID-19 vaccine and changes in behaviors affect influenza circulation this season????



Key Message: Nonpharmaceutical Interventions

 Nonpharmaceutical interventions (NPI) for prevention of COVID-19 such as universal masking*, physical distancing, avoiding group gatherings, staying home when sick, and limiting travel will likely contribute to prevention of influenza, but do not replace influenza vaccination and chemoprophylaxis with influenza antivirals





*CDPH FAQs on Face Coverings 9/1/2021: https://www.cdph.ca.gov/ Programs/CID/DCDC/Pages/COVID-19/Face-Coverings-QA.aspx



HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM

Key Messages: Influenza Vaccination

- Vaccination is the most effective tool to prevent influenza and its serious complications
- Influenza and its serious complications
 While the effectiveness of influenza vaccines for prevention of all influenza infections varies by season, these vaccines prevent
- severe disease, ICU admissions, and death
- Influenza vaccine is especially important for
 - SNF residents at risk of severe illness and death
 - SNF HCP to protect themselves and their vulnerable residents

www.cdph.ca.gov/Programs/OPA/Pages/Communications-Toolkits/Fight-Flu-Together.aspx

¹www.ncbi.nlm.nih.gov/pmc/articles/PMC7300995/pdf

² www.medrxiv.org/content/10.1101/2020.06.29.20142505v1.full.pdf





Key Messages: Influenza Vaccination (cont'd.)

- Influenza vaccine may be given at the same time as SARS-CoV-2 vaccine
- Influenza vaccine will neither prevent nor increase the risk of infection with SARS-CoV-2
 - Data from Italy¹ and Brazil² demonstrated a significant reduction in mortality from COVID-19 among influenza vaccine recipients
- See CDPH website for communication tools in Spanish and English, updated 9/21/2021 (<u>https://www.cdph.ca.gov/Programs/OPA/Pages/Communications-</u> <u>Toolkits/Fight-Flu-Together.aspx</u>)



¹www.ncbi.nlm.nih.gov/pmc/articles/PMC7300995/pdf ²www.medrxiv.org/content/10.1101/2020.06.29.20142505v1.full.pdf



13

PublicHeal

Key Message: Provide Influenza Vaccine to SNF HCP

- 2018-2019: 67.9% of HCP working in long term care facilities (LTCF) in the U.S. were vaccinated against influenza during the 2018-19 season, compared with 95% coverage in acute care hospitals
- 2019-20: vaccination coverage in LTCF was 69.3%, but 85-89% in LTCF with employer requirement and programs on site



CDC Influenza (Oct.1, 2020): www.cdc.gov/flu/fluvaxview/hcp-coverage_1920estimates.htm#five

Flu Vaccine Coverage During 2020-21 Season

- Early estimates of flu vaccine coverage during 2020-21 season in the United States
 - Adults: 50-55%
 - Children: 58.2%
 - Pregnant: slight decrease
- HCP in California acute care hospitals: 79%
 - Decreased from 85% pre-pandemic
 - Only 23% of hospitals met goal of 90%



Recommendations for the Prevention and Control of Influenza in California Skilled Nursing Facilities (SNF) during the COVID- 19 Pandemic

California Department of Public Health (CDPH) Updated October 2020

www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/SNF_DetectAndControl Outbreaks.aspx



Organization of the Guidance Document

- Introduction
- Key Messages
- **Table 1**: Comparison of clinical characteristics of COVID-19 and influenza
- Table 2: Planning for influenza illness and outbreaks in SNF
- **Table 3**: Identifying and Controlling Influenza Outbreaks in SNF
- Glossary
- Resources
- Appendix A. Sample Surveillance Case Log of Residents with Acute Respiratory Illness and/or Pneumonia
- Appendix B. Sample Surveillance Case Log of Healthcare Personnel with Acute Respiratory Illness and/or Pneumonia



TABLE 1. Similarities and Differences BetweenSeasonal Influenza Virus and SARS-CoV2

Same: Fever, chills, cough, shortness of breath or difficulty breathing, fatigue, sore throat, runny or stuffy nose, myalgias, headache, vomiting and diarrhea, cardiac complications

Differences:

Select Characteristics	Influenza	COVID-19							
Peak symptoms	During days 3-7 of illness	During week 2-3 of illness							
Incubation Period	1-4 days (median 2 days)	14 days (median 5 days)							
Case-Fatality Rate	0.1%	0.25-3.0%							
Primary route of transmission	Droplet Short-range aerosol possible	Droplet, short-range aerosol Fomite and fecal-oral less important							
Recommended PPE	Surgical mask; gown and gloves if high contact activity	N95 respirator, eye protection, gown, gloves AIIR if aerosol generating procedure							



HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM Key messages: Testing and Resident Placement & Cohorting

- Testing: Once influenza is circulating in the community, always test residents with symptoms & signs of COVID-19 or influenza for <u>both</u> viruses
- **Resident placement**: Maintain symptomatic resident in current room and implement COVID-19 transmission-based precautions pending test results
- **Cohorting:** Avoid movement of residents with suspected or confirmed influenza *between* COVID-19 cohorts

Respiratory Illness Quicksheet: www.cdph.ca.gov/Programs/CID/DCDC/ CDPH%20Document%20Library/Immunization/FluAndRespiratoryIllnessOutbreak Quicksheet.pdf



Table 2. Planning for Management of Influenza Illnessand Outbreaks in SNF During the COVID-19 Pandemic

ACTIONS	RESIDENTS	НСР	FAMILY MEMBERS/VISITORS
Educate	\checkmark	\checkmark	\checkmark
Update influenza vaccination plan	\checkmark	\checkmark	
Review pneumococcal vaccination status of residents	\checkmark		
Update plan for daily active ILI surveillance	\checkmark	\checkmark	
PLAN TO TEST RESIDENTS and HCP WITH SYMPTOMS OF COVID OR FLU FOR BOTH VIRUSES	~	~	
Adjust plan for influenza prevention and outbreak management for COVID-19	\checkmark	\checkmark	\checkmark
Update plan for obtaining and using influenza antiviral agents	\checkmark		
Develop process for after action evaluation of plan	\checkmark	\checkmark	

Before an Outbreak Occurs:

Plan Your Influenza Vaccination Program

- Key elements of an influenza vaccination plan
 - SNF are responsible for
 - Providing influenza vaccine to residents and HCP on site
 - Providing rationale and referral to sites for vaccine to families
 - Standing orders
 - Minor illness, SARS-CoV-2 exposure are not contraindications; be alert to diagnostic uncertainty if fever post influenza vaccination (uncommon)
 - Designate a specific influenza vaccination week to complete most vaccination, but continue throughout the season
 - Identify flu vaccine champions
 - Track vaccine administrations



www.izsummitpartners.org/content/uploads/2019/02/guidance-for-developing-a-flu-vax-reqtpolicy-for-hcp-in-post-acute-and-ltcf.pdf

Table 3. Identifying Influenza Outbreaks in SNF

ACTIONS	RECOMMENDATIONS									
1.Perform daily active surveillance	• During influenza season, usually October-March, conduct daily active surveillance for acute upper									
for respiratory illness in	respiratory illness and pneumonia among residents and HCP until at least 1 week after the last									
residents and HCP	confirmed case of influenza using a line list (see Appendices A and B for examples of line lists)									
(Appendix A, B)	 The respiratory illness line lists are different from the line lists used to track serial testing result 									
	for COVID-19 (contact covHAI@cdph.ca.gov for COVID-19 line list template); continue to use									
	COVID-19 linelist for tracking serial test results									
	 Include individuals with current or recovered COVID-19 who have new onset of respiratory 									
	symptoms									
Initiated(date)	 Record specific locations of ill residents and HCP assignments and include information about sick 									
	HCP and sick visitors, as available									
Complete(date)	 Review line list daily and take actions needed if suspect influenza cases are identified. 									
2. Use <u>diagnostic testing</u>	• Test residents with onset of respiratory symptoms for both influenza and SARS-CoV-2 at the same									
(www.cdc.gov/flu/professionals/di	time to confirm the diagnosis; contact the local health department for assistance obtaining real-									
agnosis/overview-testing-	time RT-PCR testing for influenza with rapid turn-around time.									
methods.htm) for influenza and	 Wherever available, use multiplex influenza A and B and SARS-CoV-2 (Flu SC2) 									
SARS-CoV-2:	(www.cdc.gov/flu/professionals/diagnosis/table-flu-covid19-detection.html) tests; multiplex point-									
 Multiplex molecular assays 	of-care (POC) testing for both influenza and SARS-CoV-2 should be considered for rapid evaluation									
 Influenza A, B, and SARS- 	of symptomatic individuals, followed by confirmatory real-time RT-PCR testing for negative results.									
CoV-2	• The lower sensitivity of antigen detection rapid influenza diagnostic tests (RIDTs) increases the risk									
Rapid molecular assays	of not identifying an influenza case; a negative RIDT in a symptomatic individual should be									
Rapid antigen detection	confirmed with real-time RT-PCR testing for influenza, even when the SARS-CoV-2 test is positive.									
assays	 The lower sensitivity of POC antigen tests for SARS-CoV-2 increases the risk of not identifying a 									
	COVID-19 case; a negative POC antigen test for SARS-CoV-2 in a symptomatic individual should be									
	confirmed with real-time RT-PCR testing for SARS-CoV-2, even when the influenza test (RIDT or									
1	otherwise) is positive									



HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM Surveillance for Acute Upper Respiratory Illness (URI) and Pneumonia

- Conduct daily active surveillance for acute URI and pneumonia in residents and in HCP
 - Include COVID-19 recovered individuals who develop new onset of respiratory symptoms
 - Review linelist daily to determine if testing or isolation needed, or definition of outbreak is met

 $\,\circ\,$ Review absenteeism of HCP

Rør	idont Ido	atifical	ti nn	Yac Hir	cia.s ary	Illasse description						Test for the second sec			Covin-19 Test Recutt			Recults	Anti-viral Treatment	Antibiotio		Illine s cutoome								
•	Age	Secc (MP)	Building. Unit, Room, Bed	Influenza (YAN)	Preumococo al (Y/N)	Date criset Illiness	Migheek temperature	Cough (Y/N)	Metalsofter Igue (Y/M)	Chiltshigor s (%N)	Som through (n/N)	Arthraig lai' myatgia (mn)	Change in respiratory status (e.g., sputum)	Proumonia (mN)	COR confirmed (Y/N)	Date spectmen collected	RT-PCR Besults	Rapid antigen (+/- (ND)	Date spectmen collected	Type of test	Postegind	Gram state	Sputurm culture	Dates started/Date e ended	Duto startod (Dut e end od	Influenza (YAN)	Preumonia (%/%)	Hongstadized (Y/N)	No. Days hospitalized	Died (Y/N) If yes, date
																														_
				•			•				· · ·				-															



Testing SNF Residents with Symptoms During the COVID-19 Pandemic

- Test any resident with symptoms of COVID-19 or influenza for both viruses to inform infection control practices and treatment
 - Use flu/SARS-CoV-2 multiplex tests (Flu SC2) whenever possible
 - Rapid influenza *molecular* tests (NAAT) rather than rapid influenza antigen tests (RIDTs) are preferred for improved sensitivity, at least to establish the presence of an outbreak
 - Confirm a negative rapid antigen test for SARS-CoV-2 in a symptomatic individual with RT-PCR
 - A positive test for either influenza or SARS-CoV-2 does not exclude the possibility of a co-infection
 - Use a broad respiratory virus panel (RVP) to test for other respiratory viruses, e.g., RSV, adenovirus, parainfluenza, human metapneumovirus, if influenza and SARS-CoV-2 tests are negative and an outbreak of respiratory illness is suspected.



www.cdc.gov/flu/professionals/diagnosis/table-flu-covid19-detection.html www.cdc.gov/flu/professionals/diagnosis/overview-testing-methods.html

Collection of Specimens for Testing

- Follow directions in test kits used
- Influenza
 - When: 24-72 hours after symptom onset is optimal
 - What: A nasopharyngeal or combined throat and midturbinate nasal specimens provide the most accurate results
 - How: Follow directions that accompany the rapid influenza testing kit; use a swab with a synthetic tip (e.g., polyester or Dacron[®]) and an aluminum or plastic shaft.
 Specimens collected with swabs made of calcium alginate are NOT acceptable.





Establish the Presence of an Influenza Outbreak

- Definition
 - 2 residents with onset of influenza-like illness within 72 hours of each other AND at least 1 resident with laboratory confirmed influenza, preferably by molecular assay (RT-PCR)
 - Consult LHD for guidance
- Influenza outbreaks might occur separately or concurrently with COVID-19 outbreaks
 - The presence of a confirmed influenza outbreak does not preclude the possibility of a COVID-19 outbreak, nor does a COVID-19 outbreak preclude the possibility of an influenza outbreak



Communication:

This is what you have been planning for!



- As soon as an influenza outbreak is established, notify:
 - Facility infection preventionist, administration, medical director, staff
 - Local health department, CDPH L&C district office
 - Residents, family members, visitors
- Post signs at facility entrances: Reminders about vaccine
 - Add tissues and covered waste receptacles to COVID-19 materials and signage at entrance
- Remind HCP of their specific tasks according to the influenza outbreak plan
 - Document assignments and dates initiated and completed
- Restrict visitation and admissions during an active flu outbreak





27

Transmission-based Precautions and Cohorting

- General principles
 - PPE practices for SARS-CoV2 will protect against flu, but PPE practices for flu won't protect against SARS-CoV-2
 - Do not move residents with suspected or confirmed influenza between COVID-19 cohorts; for example, do not move a resident with suspected or confirmed influenza from a yellow (COVID-19 exposed or observation) to a green (COVID-19 unexposed or recovered) area
 - Residents with suspected or confirmed influenza may be cohorted together within the same COVID-19 zone
 - During an outbreak of COVID-19 and flu, each COVID-19 zone (Red, Yellow) may require a separate area for flu



Transmission-based Precautions and Cohorting

Source control

- Emphasize masks for HCPs, residents, and visitors to prevent transmission of flu, using signage
- Prioritize single-bed rooms, where available, for residents with suspected flu pending test results
 - If single rooms are unavailable, ill residents may remain in their room with separation of <u>></u> 6 feet and privacy curtain between residents
- Use COVID-19 transmission-based precautions while test results pending



When Influenza Only is Confirmed: PPE

- Droplet precautions plus face shield
 - Continue for <u>></u> 7 days after illness onset (24 hours after resolution of fever and respiratory signs)
- Don N95 plus face shield, gowns and gloves for aerosol generating procedures
- Add gloves and gowns per Standard precautions when contact with blood or body fluids is anticipated; add Enhanced Standard precautions for high contact activities with residents at risk for MDRO
- Maintain residents in their rooms when safe and restrict from activities in common areas including meals
- Place facemask on resident and have resident perform hand hygiene and don clean clothes if he/she needs to leave room for medical reasons

HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM

Adherence Monitoring



- Perform repeated audits of HCP adherence to masking for source control, hand hygiene and other infection control precautions
 - Secret Shopper
 - Immediate feedback to HCP when lapses are observed
- Perform audits of residents wearing masks when HCP are in the room with feedback to resident and staff
- Report trends in audit results to SNF administrators and leaders
- Post de-identified adherence monitoring data in HCP break or charting areas



HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM

Antiviral Agents for Influenza: Treatment

- Begin anti-viral treatment as soon as possible, but within 48 hours of symptom onset
- When there is ongoing transmission of influenza and not SARS-CoV-2, do not wait for test results before initiating Rx
- Consult resident's PCP for any necessary dose adjustments in residents with underlying conditions, such as renal impairment
- If illness progresses for 72 hours on therapy, consult LHD for evaluation of possible drug resistance



Antiviral Agents for Influenza: Chemoprophylaxis

- When an influenza outbreak is established, provide influenza antiviral chemoprophylaxis with the currently recommended antiviral agent at the recommended dosage regimen to all nonill residents in the entire facility or in the building or unit affected, regardless of vaccination status
- Prioritize as follows:
 - Roommates, residents on the same floor or unit as residents with active influenza
 - $\,\circ\,$ Residents in the same building with shared HCP
- Duration: > 14 days and > 7 days after the last known case was identified
- Re-test for flu and SARS-CoV-2 any resident who develops signs or symptoms of ILI after receiving an antiviral agent for <u>></u> 72h



Manage Healthcare Personnel

- Ensure vaccination
- Instruct not to work respiratory infection symptoms
- If symptoms develop at work: ensure face mask in place, notify supervisor, leave promptly, test for SARS-CoV-2 and flu
- If influenza pos. and SARS-CoV-2 neg.
 - HCP follows facility policy for return to work for influenza: at minimum do not return to work until afebrile >24 hours without antipyretic treatment and with improvement in respiratory symptoms or no earlier than 5 days after onset
- Consider referring HCP for antiviral chemoprophylaxis if:
 - o < 14 days after receiving vaccine (must be > 14 days after LAIV4)
 - Not vaccinated due to contraindications
 - $\circ~$ At high risk for complications



Determine End of Influenza Outbreak

- Consult LHD
- No new cases of influenza identified for at least 1 week after the last confirmed case of influenza
- Resume new admissions to previously affected units, or as determined by COVID-19 status
- Notify:
 - Facility infection preventionist, administration, medical director, HCP
 - Local health department
 - L&C district office
 - Residents, family members, visitors
- Perform assessment of program and begin plan for next year



Conclusions

- Unprecedented times require preparation for flu and SARS-CoV-2 co-circulation: *Prepare for the worst, hope for the best*
- Planning ahead for prevention of adverse outcomes associated with influenza requires a strong flu vaccination program for residents and staff with education for families
- Continue non-pharmaceutical intervention (NPI) practices
- Ongoing surveillance and evaluation will detect unpredicted events
- Communication between LHD and facilities is key

